Poster and Platform Presentations -
Parkinson's Disease Center and Movement Disorders Clinic

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2017

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    21st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)
    • Whole exome sequencing in essential tremor.

      Alfradique-Dunham I, Robak LA, Kaw A, Fagbongbe OI, Ternes K, Young E, et al.

    • Effect of deutetrabenazine on QTcF interval in the AIM-TD study: A 12-week, phase III, randomized, double-blind, placebo-controlled study.

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study.
      [Previous presented]

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Addressing involuntary movements in tardive dyskinesia (aim-td): Efficacy, safety, and tolerability of fixed-dose deutetrabenazine for the treatment of tardive dyskinesia.
      [Previous presented]

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • A phase 2, open-label, dose-escalating study to evaluate the safety and preliminary efficacy of daxibotulinumtoxinA for injection (RT002) in isolated cervical dystonia.
      [Previously Presented]

      Comella C, Jankovic J, Truong D, Brashear A, Patel A, Evatt M, et al.

    • Clinical relevance of treatment with onabotulinumtoxinA in patients with cervical dystonia: Results from the CD probe study.

      Dashtipour K, Mari Z, Jankovic J, Adler C, Schwartz M, Brin M

    • Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study.
      [Previous presented]

      Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies.
      [Previous presented]

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Treatable rare movement disorders.

      Gatto E, Jinnah H, Espay A, Jankovic J, Bhatia K, Rodriguez M, et al.

    • A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome.

      Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, et al.

    • Results from a phase 1b multiple ascending-dose study of prx002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.

      Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, et al.

    • Leg stereotypy disorder: Phenomenology and prevalence.

      Jankovic J, Lotia M, York MK, Strutt AM

    • Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in clinical global impression of change (CGIC) with deutetrabenazine treatment in tardive dyskinesia (TD).
      [Previous presented]

      Jimenez-Shahed J, Fernandez H, Hauser R, Davis M, Factor S, Isojärvi J, et al.

    • Deutetrabenazine is associated with an improvement in involuntary movements in patients with tardive dyskinesia (TD) as seen by the high proportion of responders to deutetrabenazine treatment in the AIM-TD study.
      [Previous presented]

      Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al.

    • Deutetrabenazine treatment response by concomitant dopamine-receptor antagonists in the phase III, randomized, double-blind, placebo-controlled AIM-TD trial in tardive dyskinesia (TD).
      [Previous presented]

      Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al.

    • Emotion regulation and neuropsychological status in psychogenic subtypes.

      Scott B, Strutt A, Lundberg-Love P, Schmitt A, Jankovic J, Bowers D

    • Hemidystonia associated with Alexander disease.

      Vijayakumar D, Lewis RA, Fuller GN, Dhar SU, Machol K, Robak L, et al.

    American Psychiatric Association (APA)
    170th Annual Meeting in San Diego, Calif. (May 20-24, 2017)
    • Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study.

      Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study.

      Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al.

    • Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    • Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies.

      Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al.

    American Academy of Neurology (AAN)
    69th Annual Meeting in Boston, Mass. (April 22-28, 2017)

2016

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    20th International Congress of Parkinson's Disease and Movement Disorders in Berlin, Germany (June 19-23, 2016)
    • Understanding, predicting, and preventing falls in progressive supranuclear palsy.

      Bluett BR, Litvan I, Cheng S, Juncos J, Bordelon Y, Riley DE, et al.

    • A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD).

      Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo W, LeDoux MS, et al.

    • Objectives of the MDS rare movement disorders study group.

      Gatto EM, Albanese A, Bathia K, Cardoso F, Cesarini M, Chade A, et al.

    • The National Parkinson Foundation mentoring and networking program: Phase I the process.

      Hunter CB, Palmentera PR, Vernon B, Silver A, Arney K, Fleisher J, et al.

    • A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.

      Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy TK, Shprecher D, et al.

    • Predictors of onabotulinumtoxinA treatment response in patients with cervical dystonia.

      Jankovic J, Marc S, Aubrey A

    • Apraclonidine in blepharospasm.

      Jankovic J, Vijayakumar D, Wijemanne S

    • One to 40 years later: Delayed effects of brain radiation presenting as parkinsonism.

      Jimenez-Shahed J, Itin I, Mehanna R

    • Globus pallidus interna oscillatory activity differentiates tics from voluntary movements and the Parkinsonian resting state.

      Jimenez-Shahed J, Telkes I, Viswanathan A, Ince NF

    • Apraclonidine in the treatment of ptosis.

      Wijemanne S, Vijayakumar D, Jankovic J

    American Academy of Neurology (AAN)
    68th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)
    • Success of targeting rationale in deep brain stimulation for Parkinson's disease.

      Farcas A, Jimenez Shahed J

    • A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome.

      Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al.

    • Safety profile of unblinded internal pallidal deep brain stimulation for medically refractory Tourette syndrome.

      Niemann N, Strutt A, Viswanathan A, Jimenez Shahed J

    • A case of neurosarcoidosis masquerading as subacute inflammatory demylelinating polyneuropathy.

      Rizk C, Savitt D, Jain S, Kass J

    • Paradoxical worsening dystonia after deep brain stimulation in a patient with neurodegeneration with brain iron accumulation.

      Tarakad A, Jimenez Shahed J

2015

Collapse All | Expand All

 

    Movement Disorder Society (MDS)
    19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, Calif. (June 14-18, 2015)
    • A randomized controlled trial of telemedicine for Parkinson's disease (Connect.Parkinson) in the United States: Interim assessment of investigator and participant experiences.

      Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, et al.

    • XCiDaBLE: Observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the USA.

      Fernandez HH, Jankovic J, Pagan F, Greeley D, Sethi K, Verma A

    • Progressive supranuclear palsy and statin use.

      Fuentes A, Standaert D, Marras C, Riley D, Hall D, Kluger B, et al.

    • DBS experience at a tertiary care referral center.

      Jimenez-Shahed J, Keller J, Hunter C, Jankovic J

    • American multiple system atrophy natural history study.

      Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al.

    • Cervical dystonia and work productivity: Results from the cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy.

      Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al.

    • Dystonia-spasticity in a patient with a novel SLC25A12 mutation.

      Parnes M, Robak L, Shulman JM, Stocco A, Jankovic J

    • Clinical characteristics of tetrabenazine-induced parkinsonism.

      Shah D, Jimenez-Shahed J

    • Clinical utility of apraclonidine in ptosis.

      Wijemanne S, Jankovic J

    American Academy of Neurology (AAN)
    67th Annual Meeting in Washington, DC (April 18-25, 2015)
    • Reliability of the severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2).
      [Oral Presentation]

      Comella C, Perlmutter J, Jinnah H, Factor S, Goetz C, Adler C, et al.

    • XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort.

      Fernandez HH, Jankovic J, Holds J, Lin D, Burns J, Sethi K, et al.

    • Effect of cigarette smoking on outcomes of acute ischemic stroke treated with intravenous thrombolysis: Is there any paradox in the brain?

      Hussein H, Niemann N, Stuck L, Qureshi A

    • The impact of cervical dystonia on work productivity: An analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE).

      Molho E, Stacy M, Gillard P, Charles P, Adler C, Jankovic J, et al.

    • Dystonia-spasticity in a patient with a novel SLC25A12 mutation.

      Parnes M, Robak L, Shulman J, Stocco A, Jankovic J

    • SUNCT responding to botulinum toxin.

      Wijemanne S, Jankovic J

<2014

Collapse All | Expand All